Michael Neely, MD
Dr. Neely is the director of the University of Southern California Laboratory of Applied Pharmacokinetics, which has been at the forefront of nonparametric population pharmacokinetic modeling techniques and dose optimization for individual patients for over 35 years. He is an Associate Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at Children’s Hospital Los Angeles. His research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. He has a Master of Science degree in Clinical and Biomedical Investigations from USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling. He is a member of the United States Food and Drug Administration Anti-infective Drug Advisory Committee and board certified in pediatrics, pediatric infectious diseases and a Fellow of the American College of Clinical Pharmacology. He completed a four-year NIH career development award, and is the Principle Investigator for two R01 awards from the NIH totaling over 6 million dollars over 5 years to develop and apply pharmacometric techniques to anti-infective therapy in populations and individual patients. Dr. Neely has over 50 publications in peer-reviewed journals, and is invited to give talks and workshops on dose individualization and optimization worldwide.
Teresa Virgallito has specialized in physical and mechanical encapsulation, ingredient engineering, food law regulations and food safety, microbiology and chemical instrumentation. Before CURE, Virgallito was the EVP of Chemistry Holdings, Inc. She has developed drug delivery and formulation solutions for Procter & Gamble, Kraft, Unilever, Cargill, the U.S. Army, and the U.S. Navy. Through her research and commercialization endeavors, she has gained a wealth of knowledge and expertise in regard to the following encapsulation methods: Co-acervation, In-situ Polymerization, Interfacial Polymerization, Fluid Bed Technology, Spray Chilling, Hot Melt Systems, Prilling, Pan Coating, Phase Separation, and Spray Drying. Teresa has been active in the Controlled Release Society for several years and sits on five additional CRS committees.
Mr. Willner is the founder of Willner Properties Services, Inc., a Pennsylvania-based real estate development, leasing, and management company specializing in both commercial and residential properties. He is also the founder of Willner Capital, Inc., a Florida-based investment concern that has played an activist role with several publicly traded companies. Mr. Willner has been investing in biotechnology, technology, and security-related companies for over 30 years, and recently has been more focused on investing in cannabis-related pharmaceutical companies. Mr Willner is both an Attorney and a Certified Public Accountant, having held positions at New York City-based Milbank, Tweed, Hadley & McCloy, an international law firm, and Arthur Andersen & Company as a tax accountant. He has served on the Board of Directors of Meridian Bank, a Pennsylvania state-chartered commercial bank, as well as the Vice Chairman of the Board of Directors of Intervoice, Inc. Mr Willner holds a Juris Doctor degree from Emory University Law School.